Dr Reddy's Laboratories Net Profit Margin 2010-2024 | RDY

Current and historical net profit margin for Dr Reddy's Laboratories (RDY) from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue. Dr Reddy's Laboratories net profit margin for the three months ending September 30, 2024 was .
Dr Reddy's Laboratories Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2024-09-30 $3.58B $0.63B 17.73%
2024-06-30 $3.45B $0.66B 19.22%
2024-03-31 $3.35B $0.67B 19.91%
2023-12-31 $3.23B $0.62B 19.21%
2023-09-30 $3.19B $0.61B 19.04%
2023-06-30 $3.15B $0.57B 18.05%
2023-03-31 $2.99B $0.55B 18.32%
2022-12-31 $2.95B $0.45B 15.14%
2022-09-30 $2.83B $0.39B 13.73%
2022-06-30 $2.82B $0.38B 13.60%
2022-03-31 $2.83B $0.31B 11.00%
2021-12-31 $2.83B $0.36B 12.69%
2021-09-30 $2.79B $0.27B 9.58%
2021-06-30 $2.67B $0.24B 8.84%
2021-03-31 $2.59B $0.24B 9.10%
2020-12-31 $2.38B $0.27B 11.39%
2020-09-30 $2.32B $0.19B 8.10%
2020-06-30 $2.34B $0.24B 10.24%
2020-03-31 $2.32B $0.26B 11.18%
2019-12-31 $2.46B $0.24B 9.63%
2019-09-30 $2.38B $0.38B 16.14%
2019-06-30 $2.24B $0.30B 13.44%
2019-03-31 $2.23B $0.27B 12.22%
2018-12-31 $2.15B $0.25B 11.74%
2018-09-30 $2.20B $0.24B 10.77%
2018-06-30 $2.21B $0.21B 9.45%
2018-03-31 $2.18B $0.15B 6.92%
2017-12-31 $2.26B $0.16B 7.02%
2017-09-30 $2.22B $0.18B 7.93%
2017-06-30 $2.21B $0.18B 7.98%
2017-03-31 $2.17B $0.19B 8.57%
2016-12-31 $2.09B $0.14B 6.56%
2016-09-30 $2.15B $0.16B 7.27%
2016-06-30 $2.22B $0.22B 10.03%
2016-03-31 $2.34B $0.30B 12.93%
2015-12-31 $2.43B $0.38B 15.64%
2015-09-30 $2.44B $0.38B 15.72%
2015-06-30 $2.40B $0.37B 15.20%
2015-03-31 $2.40B $0.36B 14.98%
2014-12-31 $2.36B $0.36B 15.12%
2014-09-30 $2.32B $0.37B 15.76%
2014-06-30 $2.27B $0.38B 16.80%
2014-03-31 $2.17B $0.35B 16.20%
2013-12-31 $2.20B $0.38B 17.10%
2013-09-30 $2.15B $0.35B 16.05%
2013-06-30 $2.16B $0.31B 14.46%
2013-03-31 $2.14B $0.31B 14.56%
2012-12-31 $2.05B $0.27B 13.40%
2012-09-30 $2.05B $0.30B 14.77%
2012-06-30 $1.96B $0.29B 14.67%
2012-03-31 $1.95B $0.29B 14.72%
2011-12-31 $1.88B $0.29B 15.63%
2011-09-30 $1.78B $0.26B 14.47%
2011-06-30 $1.74B $0.26B 14.88%
2011-03-31 $1.66B $0.25B 14.76%
2010-12-31 $1.57B $0.21B 13.17%
2010-09-30 $1.52B $0.03B 2.24%
2010-06-30 $1.48B $0.02B 1.01%
2010-03-31 $1.50B $0.02B 1.40%
2009-12-31 $1.53B $-0.21B -13.63%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $11.978B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00